Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are not doing other therapies for pain (physical therapy, chiropractic management, pool)~* Women between age 21 and 50 who plan to deliver at Loyola or Gottlieb~* Pain Numeric Rating Scale (NRS) on average of greater than or equal to 5/10 at Visit 1~* Pain must be between the upper level of the iliac crests and the gluteal folds in conjunction with or separately from pain in the pubic symphysis and influenced by position and locomotion~* 2/4 positive physical examination tests on the symptomatic side including the P4 test, the LDL test, pubic symphysis palpation and the acute straight leg rise (ASLR)~Exclusion Criteria:~* Women presenting with PGP in the first or third trimester (\<13 weeks gestation or \>28 weeks gestation)~* Women with pubic symphysis (anterior) pain alone~* Women who do not plan to deliver a baby at Loyola or Gottlieb~* Pain above the upper level of the iliac crest~* History of lumbar or pelvic fracture, neoplasm, inflammatory disease, active urogenital infection or active gastrointestinal illness, current physical therapy or other therapies for PGP, or previous surgery of the lumbar spine, pelvic girdle, hip joint or femur~* History or signs of radiculopathy or other systemic neurologic disease~* Women with diabetes or gestational diabetes

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
- Placebo (Type: PLACEBO_COMPARATOR): Participant's randomized to this condition will receive a placebo injection once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).